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SYNTHETIC HYPE:  A SKEPTICAL VIEW OF 
THE PROMISE OF SYNTHETIC BIOLOGY 
Jonathan Kahn, J.D., Ph.D* 
I.  INTRODUCTION 
There are diverse definitions of “synthetic biology.”  For the 
purposes of this article, a relatively early article in the journal Nature 
Reviews Genetics provides a reasonably useful definition:  “A discipline 
that embraces the emerging ability to design, synthesize and evolve new 
genomes or biomimetic systems.”1  The basic idea of synthetic biology is 
to make biology more like engineering, creating standardized biological 
“parts” that can be combined to redesign existing biological systems and 
create entirely new ones that do not already exist in the natural world.  It 
is aptly represented by the concept of “BioBricks,” a trademarked term 
describing “standard biological parts [that] a synthetic biologist or 
biological engineer can [use to] program living organisms in the same 
way a computer scientist can program a computer.”2 
Synthetic biology has been around in some form or another for 
several years (or even decades, if one considers recombinant DNA to be 
a technology of synthetic biology), but it came to national prominence in 
May 2010, when the J. Craig Venter Institute announced it had created 
the world’s first self-replicating synthetic genome in a bacterial cell of a 
different species.  Soon thereafter, President Obama asked his 
Presidential Commission for the Study of Bioethical Issues (“PCSBI”) to 
explore and advise him of the major issues presented by current and 
promised developments in the field of synthetic biology.3 
On December 16, 2010, the PCSBI issued its report, which 
Commission Chair Amy Gutmann (also President of the University of 
Pennsylvania) characterized as a comprehensive review of “‘the 
developing field of synthetic biology to understand both its potential 
                                                 
* Professor, Hamline University School of Law. 
1 Jay Shendure, Robi D. Mitra, Chris Varma & George M. Church, Advanced Sequencing 
Technologies:  Methods and Goals, 5 NATURE REVIEWS GENETICS, 335, 336 (2004), available at 
http://arep.med.harvard.edu/PGP/Shendure04.pdf; Glossary, NATURE.COM, http://www. 
nature.com/nrg/journal/v5/n5/glossary/nrg1325_glossary.html (last visited Apr. 27, 
2011). 
2 BioBricks Foundation—Info, FACEBOOK, http://www.facebook.com/pages/BioBricks-
Foundation/171198089577371?v=info (click “See All” link) (last visited Apr. 25, 2011). 
3 Transcript of Synthetic Biology Meeting, Presidential Commission for the Study of 
Bioethical Issues (July 9, 2010), available at http://bioethics.gov/cms/node/163 (last visited 
June 22, 2011).  
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rewards and risks.’”4  The Commission considered such potential 
benefits as “the development of vaccines and new drugs and the 
production of biofuels that could someday reduce the need for fossil 
fuels.”5  It also explored “the risks posed by the technology, including 
the inadvertent release of a laboratory-created organism into nature and 
the potential adverse effects of such a release on ecosystems.”6  To 
reduce any possible threat, some scientists and ethicists advised careful 
monitoring and review of the research.  Gutmann noted that the PCSBI 
“‘considered an array of approaches to regulation—from allowing 
unfettered freedom with minimal oversight . . . to prohibiting 
experiments until they can be ruled completely safe beyond a reasonable 
doubt.’”7  The Commission ended up choosing what Gutmann called a 
“‘middle course’,” advocating that the government exercise “‘[p]rudent 
vigilance’” so that when “‘federal oversight is needed[, it] can be 
exercised in a way that is consistent with scientific progress.’”8  The 
Commission also recommended several “steps in order to minimize risks 
and to foster innovation.”9  It stated that “[r]isk assessment activities 
across the government need to be coordinated and field release 
permitted only after reasonable risk assessment,” and further 
recommended that: 
Recognizing that international coordination is essential 
for safety and security, the Department of State, in 
concert with the Department of Health and Human 
Services and the Department of Homeland Security, 
should collaborate with governments around the world, 
as well as leading international organizations, such as 
the World Health Organization to promote ongoing 
dialogue about emerging technologies like synthetic 
biology.10 
That same day, a coalition of more than thirty environmental groups 
sent a joint letter to the PCSBI criticizing the failure to call for tougher 
                                                 
4 Press Release, Presidential Commission for the Study of Bioethical Issues, Presidential 
Commission on Bioethics Calls for Enhanced Federal Oversight in Emerging Field of 
Synthetic Biology 1 (Dec. 16, 2010),  available at http://www.bioethics.gov/documents/ 
synthetic-biology/PCSBI-Synthetic-Biology-Report-Press-Release-12.16.10.pdf (last visited 
Mar. 3, 2011). 
5 Id. at 2. 
6 Id. 
7 Id. at 1. 
8 Id. 
9 Id. at 2. 
10 Id. 
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precautions, including a moratorium, until scientists prove such 
organisms are safe.11  The letter argued that the Commission’s tentative 
approach amounted to an abdication of the government’s role to provide 
effective oversight of emerging technologies, and urged the PSCBI to  
adopt the “precautionary principle” as a guide to regulatory oversight, 
in place of “‘prudent vigilance.’”12  As stated in the letter, the 
precautionary principle requires:  “‘When an activity raises threats of 
harm to human health or the environment, precautionary measures 
should be taken even if some cause and effect relationships are not fully 
established scientifically.  In this context the proponent of an activity, 
rather than the public, should bear the burden of proof.’”13  The coalition 
was concerned with many of the same questions of biosecurity and 
environmental impact that occupied the PCSBI, but reached very 
different conclusions about how to address them.14 
In this Article, I too would like to urge precaution, but a different 
sort of precaution based on broader political and economic concerns 
rather than technical ones.  Specifically, I would like to mark three 
related dynamics, which place the current buzz around synthetic biology 
in a broader context.  These dynamics are not necessarily distinctive to 
synthetic biology, but perhaps for that very reason they may carry added 
weight.  First is the place of synthetic biology as the latest entry in the 
procession of what I call the “receding horizons of biotechnological 
promise.”  Second is the excitement generated by the related promise of 
finding seemingly direct technological fixes for otherwise complex and 
messy social and political problems.  The third dynamic is the resulting 
tendency to locate such technological fixes in the marketplace, which 
leads to a (re)allocation of scarce public goods toward market-oriented 
solutions to common problems that might be more appropriately and 
equitably addressed through public initiatives. 
This Article, then, is less an examination of the promise and perils of 
synthetic biology per se and more of a cautionary examination of the 
challenges presented by the claims made on behalf of synthetic biology.  
It does not critique the technology as such, nor is it meant to be 
understood as science-bashing in any way.  Rather, I aim to locate claims 
made on behalf of an emerging technology in their social and political 
context.  Science is more than just theories and applications developed in 
                                                 
11 Letter from Civil Society to President's Commission on Synthetic Biology (Dec. 16, 
2010), available at http://www.geneticsandsociety.org/article.php?id=5517 (last visited 
Mar. 3, 2011). 
12 Id. 
13 Id. (italics omitted). 
14 See id. 
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the lab.  It is also a social enterprise that makes demands on people and 
institutions outside the lab.  In that regard, my basic concern here is to 
re-frame or move beyond existing debates over the ethical implication of 
synthetic biology for society in general, and consider more specifically 
the possible ethical implications of pursuing synthetic biology for other 
technologies and policies meant to address similar problems. 
II.  RECEDING HORIZONS OF BIOTECHNOLOGICAL PROMISE 
Synthetic biology appears to be the latest in a long line of claims of 
grand promise that have accompanied demands for both monetary and 
intellectual resources associated with successive major biotechnological 
undertakings over the past twenty years.  These undertakings have been 
worthy in their own right but have not, as yet, come anywhere near 
realizing the extravagant claims made by their initial promoters.  
Modern developments in biotechnology have been driven, in part, by an 
ever receding horizon of promise.  Many scholars have commented on 
the politics of promise and potential in biotechnology.15  With each new 
advance, claims are staked out for future benefits, which remain 
unfulfilled until the next new advance re-stakes the claim and re-sets the 
horizon for realizing its promise further into the future. 
The dynamic really began with the Human Genome Project (“HGP”) 
in the 1990s.  With its call for massive federal and private investments, 
the initial promoters of the HGP promised everything from a cure to 
cancer to unlocking the key to extending the life span.  Great fanfare 
attended the completion of the first draft of the human genome in 2000.  
President Clinton declared that “[i]n coming years, doctors increasingly 
will be able to cure diseases like Alzheimer’s, Parkinson's, diabetes and 
cancer by attacking their genetic roots,” 16 and Prime Minister Blair 
characterized the first draft as “a breakthrough that opens the way for 
massive advances in the treatment of cancer and hereditary diseases, and 
                                                 
15 See generally, e.g., ADAM HEDGECOE, THE POLITICS OF PERSONALISED MEDICINE:  
PHARMACOGENETICS IN THE CLINIC 9–28 (2004) (discussing the role of the sociology of 
expectation in promoting the promise of pharmacogenomics); MICHAEL FORTUN, 
PROMISING GENOMICS:  ICELAND AND DECODE GENETICS IN A WORLD OF SPECULATION 
(2008) (providing an ethnographic analysis of the power of promissory science in 
promoting the rise and fall of DeCode genetics in Iceland). 
16 Press Release, White House, Remarks by the President, Prime Minister Tony Blair of 
England (Via Satellite), Dr. Francis Collins, Director of the National Human Genome 
Research Institute, and Dr. Craig Venter, President and Chief Scientific Officer, Celera 
Genomics Corporation, on the Completion of the First Survey of the Entire Human 
Genome Project (June 26, 2000), available at http://www.ornl.gov/sci/techresources/ 
Human_Genome/project/clinton2.shtml. 
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that is only the beginning.”17  Also in attendance was Craig Venter, then 
of Celera Genomics, who similarly enthused that with knowledge from 
the genome, we now had “the potential to reduce the number of cancer 
deaths to zero during our lifetimes.”18 
Ten years and many billions of dollars later,  we are still waiting for 
these miracles.  For example, while biotechnology has contributed some 
notable advances to fighting some particular cancers (such as Herceptin 
for HER2+ breast cancer and Rituxan for non-Hodgkin's lymphoma), the 
overall death rate in the U.S. from all cancers went from 198 per 100,000 
in 2000, the year President Clinton announced the completion of the first 
draft of the human genome, to 178 per 100,000 in 2007. 19  A positive 
advance to be sure, but hardly miraculous, and possibly more 
attributable to social factors such as declining rates of smoking than to 
advances in biotechnology. 
As the initial promises from the HGP failed to materialize, successive 
new rounds of hype followed:  stem cell therapies would make the blind 
see and the lame walk; pharmacogenomics would provide 
individualized therapies to tailor medicines directly to your personal 
genetic profile; Genome Wide Association Studies (“GWAS”) would 
unravel the mysteries of common complex diseases such as diabetes; 
new initiatives, such as the Personal Genome Project would provide the 
sort of information we originally thought to glean from the HGP; the 
epigenome would provide the answers to how the genome really 
worked; and so on, and so on. 
Let us begin with stem cells.  The National Institutes of Health 
(“NIH”) declares that pluripotent stem cells “offer the possibility of a 
renewable source of replacement cells and tissues to treat a myriad of 
diseases, conditions, and disabilities including Parkinson’s disease, 
amyotrophic lateral sclerosis, spinal cord injury, burns, heart disease, 
diabetes, and arthritis.”20  Pluripotent cells have the potential to 
differentiate into almost any cell in the body and  are hence deemed to 
have the greatest potential for developing stem cell-based therapies.21  
                                                 
17 Id. 
18 Id. 
19 SEER Cancer Statistics Review 1975–2007, NAT’L CANCER INST., available at 
http://seer.cancer.gov/csr/1975_2007/browse_csr.php?section=2&page=sect_02_table.06.
html (last visited May 9, 2011). 
20 Stem Cell Information, NAT’L INSTITUTES OF HEALTH, available at 
http://stemcells.nih.gov/info/health.asp (last modified Jan. 7, 2011). 
21 See What are Stem Cells?, U. MINN. CENTER FOR BIOETHICS, available at 
http://www.ahc.umn.edu/bioethics/prod/groups/ahc/@pub/@ahc/documents/asset/a
hc_75703.pdf; Stem Cell Basics, NAT’L INSTITUTES OF HEALTH, available at 
http://stemcells.nih.gov/staticresources/info/basics/SCprimer2009.pdf (last visited Mar. 
3, 2011). 
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Pluripotent stem cells, however, have been obtainable most readily from 
research on cells from blastocysts or early stage human embryos.  This 
embroiled such research in the messy world of abortion politics, and on 
August 9, 2001, President George W. Bush announced that federal funds 
could not be used for research using human embryonic stem cells unless 
the stem cell lines had been derived prior to 9:00 p.m. EDT on August 9, 
2001.22 
Scientists sought a technical fix for the fundamental political 
problem by developing technologies that would create pluripotent stem 
cells without using embryonic material.  In 2006, researchers identified 
conditions that would allow some specialized adult cells to be 
“‘reprogrammed’” genetically to assume a stem cell-like state.23  These 
new stem cells were called induced pluripotent stem cells (“iPSCs”).24  
Independent of the fact that no new widely applicable stem cell therapies 
had yet been developed, researchers hoped that this technological fix 
would side-step the political problems presented by research involving 
material derived from human embryos.25  This avenue of research may 
indeed be very promising, but it remains largely a promise. 
To complicate matters, the limits of technology may be forcing 
politics back into the picture.  In 2010, “researchers found that iPSCs 
‘carry a memory of their past identities,’” 26 and in early 2011, they found 
that no matter what method is used to reprogram the cell “‘all of these 
methods still mutate the genes of the resulting cells.’”27  This does not 
necessarily mean that iPSCs cannot be used for developing stem cell 
therapies, but it does mean that they might not be readily substitutable 
for the pluripotent stem cells derived from embryos.  In any event, with 
the exception of a few experimental treatments for certain extremely rare 
genetic disorders and a recent treatment for macular degeneration, there 
have been no significant clinically applicable stem cell therapies yet 
developed.28 
                                                 
22 Stem Cell Information, NIH’s Role in Federal Policy, available at 
http://stemcells.nih.gov/policy/NIHFedPolicy.asp (last visited Mar. 3, 2011). 
23 NAT’L INSTITUTES OF HEALTH, supra note 21, at 2. 
24 Id.  
25 See id. at 9–12 (describing the potential application of adult stem cells). 
26 Not All They’re Cracked Up To Be?, GENOMEWEB (Mar. 3, 2011), 
http://www.genomeweb.com/blog/not-all-theyre-cracked-be; Ed Young, Worrying 
Genetic Changes In Reprogrammed Stem Cells, DISCOVER, http://blogs.discovermagazine. 
com/notrocketscience/2011/03/02/worrying-genetic-changes-in-reprogrammed-stem-
cells/ (last visited June 21, 2011). 
27 Id. 
28 Bone marrow transplants may be considered an even larger and more significant 
exception, but this is a technology first developed in the 1960s and not dependent on the 
new biotechnologies that manipulate cells at the molecular level.  See Stem Cells in Use, U. 
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Soon after stem cell therapy hit the headlines, researchers were 
calling GWAS the next great frontier of promise for realizing the benefits 
of genomic medicine.  In GWAS, the genomes from many different 
people are scanned for genetic markers that can serve to predict the 
presence of a disease.29  The idea is that such genetic markers can be used 
to understand how genes contribute to the disease and aid in the 
development of better prevention and treatment strategies.30  GWAS 
held out particular hopes for understanding the genetics of common 
complex diseases.  For example,  in 2006, the NIH Director Elias 
Zerhouni declared that, “this research approach holds great promise for 
providing an understanding of the genomic contributions to cancer.”31  
Once again, the language of promise was utilized, and once again, five 
years later, we are still waiting for that promise to materialize.  As one 
article recently noted, GWAS had so far proven unable 
to find important genes for disease in human 
populations.  In study after study, applying GWAs [sic] 
to every common (non-infectious) physical disease and 
mental disorder, the results have been remarkably 
consistent:  only genes with very minor effects have been 
uncovered.  In other words, the genetic variation 
confidently expected by medical geneticists to explain 
common diseases, cannot be found.32 
Following GWAS, the next entry into the genomic promise 
sweepstakes was epigenetics.  Epigenetics is the study of “heritable 
changes caused by the activation and deactivation of genes without any 
change in the underlying DNA sequence of the organism.”33  Such 
changes may involve the environment immediately surrounding the 
DNA, where methyl groups bind to DNA in a manner that affects their 
                                                                                                             
UTAH, http://learn.genetics.utah.edu/content/tech/stemcells/sctoday/ (last visited Mar. 
5, 2011). 
29 Genome-Wide Association Studies, NAT’L HUMAN GENOME RES. INST., 
http://www.genome.gov/Glossary/index.cfm?id=91 (last visited June 21, 2011) 
[hereinafter NHGRI, GWAS]. 
30 Id. 
31 Press Release, National Institutes of Health, Statement From the NIH on Cancer 
Genetics Findings at Johns Hopkins University (Sept. 7, 2006), available at 
 http://www.eurekalert.org/pub_releases/2006-09/nhgr-sft090606.php. 
32  Jonathan Latham and Allison Wilson, The Great DNA Data Deficit:  Are Genes for 
Disease a Mirage?, BIOSCIENCE RESOURCE PROJECT (Dec. 8, 2010) (citation and second 
parenthetical omitted), available at www.bioscienceresource.org/commentaries/article.php 
?id=46. 
33 Epigenetics, NAT’L HUMAN GENOME RES. INST., http://www.genome.gov/glossary/ 
index.cfm?id=528 (last visited June 21, 2011) [hereinafter NHGRI, Epigenetics]. 
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expression.  But broader impacts also affect epigenomic changes, 
including the environment external to an organism, drugs, diet and the 
aging process.  In 2010, Time magazine declared: 
The great hope for ongoing epigenetic research is that 
with the flick of a biochemical switch, we could tell 
genes that play a role in many diseases—including 
cancer, schizophrenia, autism, Alzheimer's, diabetes and 
many others—to lie dormant.  We could, at long last, 
have a trump card to play against Darwin.34 
Ironically, discoveries in epigenetics have, in part, led to recent 
concerns over the limitations of induced pluripotent stem cells as its 
researchers found more epigenetic changes in the iPSCs than anyone 
previously thought.35  Other than discovering how new discoveries may 
problemize earlier technological advances, it is still too early to tell 
whether epigenetics will lead to clinically useful applications any time 
soon. 
Where then do we stand with these existing technologies and some 
of their promises?  Beginning with the promises of gene therapy, it 
deserves noting that when the genetic basis for sickle cell anemia was 
characterized in 1949, it quickly became known as the first “molecular 
disease.”36  Sixty years later, there is still no genetic therapy for sickle cell 
anemia, let alone a cure.  In 1989 the CFTR gene, which is associated with 
Cystic Fibrosis, was first isolated just as the HGP was getting off the 
ground.37  Yet, as with sickle cell anemia, there is still no viable gene 
therapy available.38  The list could go on and on.  The bottom line is that 
the promises of revolutionary gene therapies made in the development 
and promotion of the multi-billion dollar HGP have yet to be realized.  
Similarly, the great hopes that stem cell therapy would cure spinal cord 
injuries and Parkinson’s disease or allow for the creation of subject-
compatible organs remain largely unfilled.  As for the GWAS, after years 
and untold billions of dollars devoted to the search for the genetic basis 
of such common complex disease as diabetes and hypertension, perhaps 
the best way to manage these diseases remains the relatively low tech 
                                                 
34 John Cloud, Why Your DNA Isn’t Your Destiny, TIME (Jan. 6, 2010), available at 
http://www.time.com/time/health/article/0,8599,1951968-2,00.html. 
35 GENOMEWEB, supra note 26. 
36 See KEITH WAILOO & STEPHEN PEMBERTON, THE TROUBLED DREAM OF GENETIC 
MEDICINE 122–25 (2006). 
37 John. R. Riordan et al., Identification of the Cystic Fibrosis Gene:  Cloning and 
Characterization of Complementary DNA, 245 SCI. 1066, 1066–73 (1989). 
38  See generally WAILOO & PEMBERTON, supra note 36, at 61–115. 
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and common sense advice given for decades:  eat better and exercise 
more.  But this therapy does not make much money for anyone. 
One area where genetic technology has led to direct applications is in 
the field of diagnostic testing.  There has been much success in this area, 
but less in terms of therapy or cures and more in terms of helping people 
make informed choices—especially reproductive choices.  Genetic 
screening for Tay-Sachs was among the early success stories.  Like sickle 
cell anemia, Tay-Sachs is a recessive genetic disorder.  This means that a 
person may carry one copy of the gene but manifest no symptoms.  If 
two carriers have a child, the child will have a one in four chance of 
getting two copies of the gene, and hence the disease.  Tay-Sachs is a 
severe, debilitating and ultimately fatal disease that usually kills children 
within a few years of birth. 39  The trait has a particularly high frequency 
among Ashkenazi Jews and French Canadians. 40  Beginning in the 1970s, 
American Jews began a concerted effort to educate their community to 
undergo preconception or prenatal screening for Tay-Sachs, leading to a 
steady decline of babies born with Tay-Sachs in the U.S. 41  This 
preconception and prenatal screening for a variety of conditions has 
since expanded dramatically and become a routine part of many 
people’s reproductive experience.42  Yet these advances remain very 
limited and non-therapeutic.  Indeed, with current advances in forensic 
uses of DNA technology, it may reasonably be said that you are more 
likely to have your DNA used to convict you of a crime today than you 
are to have it used to cure you of a disease.43 
Time and time again over the past two decades, new advances in 
biotechnology have rolled out to great fanfare and great promises.  As 
time horizons are met and promised results repeatedly fail to 
materialize, new promises are made for new technologies, each time 
pushing back the ever receding time horizon for concrete results.  To be 
clear, these advances are not failures.  Each and every one has made 
significant contributions to scientific knowledge and produced some 
limited concrete results.  But they have uniformly failed to live up to the 
hype initially put forward to promote them. 
                                                 
39 See id. at 15–18. 
40 See id. at 27. 
41 Id. at 16. 
42 See id. at 15–18. 
43 See, e.g., Troy Duster, The Molecular Reinscription of Race: Unanticipated Issues in 
Biotechnology and Forensic Science, 40 PATTERNS PREJUDICE 427, 427–29 (2006). 
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III.  THE PROMISES OF SYNTHETIC BIOLOGY 
The recent excitement over synthetic biology must be understood in 
the context of these earlier promises and their track record.  So, what are 
some of the promises made on behalf of synthetic biology?  The chair of 
the President’s Commission for the Study of Bioethical Issues listed the 
following potential benefits:  “the expeditious synthesis of vaccines in 
response to pandemics, and the ability to engineer algae and other 
microbes to spur advances in agriculture, aquaculture, biofuels, 
bioremediation, regenerative medicine, and pharmaceutical 
development and production.”44  All are worthy goals, but they are 
claims that have been made repeatedly on behalf of diverse 
biotechnological endeavors over the past twenty years.  Does this mean 
they should not be pursued?  Of course not.  But we must keep such 
claims in perspective and consider the costs of the pursuit. 
Science writer Roberta Kwok recently cautioned in the journal Nature 
that there are already some problems with synthetic biology and the 
hype around it.45  Kwok identified particular characterizations of 
synthetic biology, which she found over-hyped and in need of some 
cautious correction.  First is the claim that synthetic “BioBricks” would 
work like Legos, easily snapped together like so many parts in a 
mechanical engineering project.46  Kwok noted the “[hard] truth . . . that 
many of the parts are not well characterized, or work unpredictably in 
different configurations and conditions.”47  Second is the notion that 
synthetic biology will lead directly to the ability in effect to “rewire” cells 
to serve new purposes.  In fact, “[a]lthough computational modeling 
may help scientists to predict cell behaviour, the cell is a complex, 
variable, evolving operating system, very different from electronics.”48  
Kwok additionally argued that many biologically deconstructed and 
reassembled parts may be incompatible and noted that “[o]nce 
constructed and placed into cells, synthetic genetic circuits can have 
unintended effects on their host.”49  She noted the additional problem 
that “[s]ynthetic biologists must also ensure that circuits function 
reliably.  Molecular activities inside cells are prone to random 
                                                 
44 Amy Gutmann, Chair of the U.S. Presidential Comm’n for the Study of Bioethical 
Issues, Plenary Address at the 8th Global Summit of Nat’l Bioethics Advisory Bodies (July 
27, 2010), available at http://www.bioethics.gov/documents/synthetic-biology/Plenary-
Address-by-Amy-Gutmann-at-Singapore-Summit-07.27.10.pdf. 
45 Roberta Kwok, Five Hard Truths for Synthetic Biology, 463 NATURE 288, 288 (2010). 
46 Id.  
47 Id. 
48 Id. at 289. 
49 Id. 
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fluctuations, or noise.  Variation in growth conditions can also affect 
behaviour.  And over the long term, randomly arising genetic mutations 
can kill a circuit’s function altogether.”50  She concluded with a quote 
from Martin Fussenegger, a synthetic biologist at the Swiss Federal 
Institute of Technology (“ETH”) Zurich:  “The field has had its hype 
phase, . . . .  Now it needs to deliver.”51 
While these are largely technical problems worthy of consideration, 
they are not my primary concern in and of themselves; rather, it is the 
relation of such challenges to the broader role synthetic biology may be 
playing in framing our approaches to the very problems it aims to 
address.  To be clear, each of the initiatives and technologies discussed 
above have much merit in their own right.  The problem is not with the 
technologies but with the hype.  Hype has consequences.  It does not 
simply generate support for science; it profoundly affects major 
decisions regarding the allocation of scarce biomedical resources and  
promotes the increasing commercialization of academia.  As Evans and 
others recently noted in a special tenth anniversary review of the HGP in 
the journal Science, “[f]ueling unrealistic expectations for predictive 
genetic testing and uncritical translation of discoveries may also distract 
our gaze from other promising approaches to preventing disease and 
improving health.”52 
IV.  THE EASY APPEAL OF TECHNOLOGICAL FIXES FOR COMPLEX SOCIAL 
PROBLEMS 
In particular, we must be wary of the appeal of a neat technological 
fix for problems that are inextricably bound up in social and political 
dynamics.  Take the promise of synthetically engineered biofuels for 
example.  In 2009, Craig Venter, now head of the new commercial 
venture Synthetic Genomics, announced that he formed a $600 million 
partnership with Exxon/Mobile to develop biofuels from algae.53  The 
promises are many:  reduced dependence on foreign oil, reduction in 
greenhouse gas emissions, and extending fuel supplies.  But these are not 
merely technical issues. 
Jim Thomas of the environmental watchdog ETC Group notes that 
such promises are based on engineering yeast and bacteria that must 
feed on biomass—organic material that is meant to replace fossil fuels.  
He raises concerns that the new political economy of synthetic biology 
                                                 
50 Id. at 290. 
51 Id. 
52 James P. Evans et al., Deflating the Genomic Bubble, 331 SCI. 861, 861 (2011). 
53  Alok Jha, Gene Scientist to Create Algae Biofuel with Exxon Mobil, GUARDIAN (July 14, 
2009), http://www.guardian.co.uk/environment/2009/jul/14/green-algae-exxon-mobil. 
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may lead to a shift in the sourcing of relevant strategic raw materials 
from farmers in the global South to fermentation vats controlled by 
agribusiness and petroleum behemoths in the North.54  Thomas goes on 
to discuss one of the early, highly-touted breakthroughs of synthetic 
biology, Amyris Biotechnologies’ development of a synthetically 
engineered version of the anti-malarial compound artemisinin.  On the 
one hand, it is a great breakthrough for providing supplies of a much 
needed drug to fight the scourge of malaria, which itself 
disproportionately affects poor countries in the global South.  On the 
other hand, Thomas argues that such advances do not come without 
costs, noting that: 
When that synthetic artemisinin goes on sale next year, 
thousands of small-scale artemesia farmers could find 
their incomes pulled from under them.  In time they 
may be joined in joblessness by rubber tappers as 
Goodyear scales up tire-rubber production from 
synthetic E. coli.  Madagascar's vanilla farmers may be 
close behind when Evolva's vanillin-in-a-vat goes 
commercial.55 
If not done thoughtfully, the drive for biomass to feed synthetic 
biology applications could also lead to clear-cutting forests or heightened 
demand for crops such as corn, leading to significant increases in global 
food prices (a phenomenon already witnessed to some degree as a 
consequence of the United States’ drive to support the expanded 
production of ethanol for fuel).56  In the end, we may decide that such 
costs are worth the price, but it is imperative that we explicitly recognize 
the implications of such developments and consider measures for 
mitigating their unintended consequences. 
With specific regard to biofuels, we should be mindful of the fact 
that even if the technological problems of creating synthetic fuels are 
solved, the political and social problems involving the global allocation 
of resources, the economic structure of fuel markets, transportation 
infrastructure, and myriad other issues contributing to energy needs and 
global climate change would persist.  The promise of an easy 
technological fix also promises to distract us from devoting the time and 
                                                 
54 Jim Thomas, The Sins of Syn Bio, SLATE (Feb. 2, 2011), http://www.slate.com/id/ 
2283299. 
55 Id. 
56 ETC GROUP, THE NEW BIOMASSTERS - SYNTHETIC BIOLOGY AND THE NEXT ASSAULT ON 
BIODIVERSITY AND LIVELIHOODS, 3–5 (2010), available at http://www.etcgroup.org/en/ 
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attention necessary to address difficult on-going political and social 
issues that are never neatly resolved but need constant consideration. 
V.  MODELS OF REGULATION AND ALLOCATIONS OF AUTHORITY 
The question then becomes, how are we to be mindful?  Or more 
specifically, what are the relative roles of public oversight/regulation 
and private action in governing this emerging technology?  Prominent 
among the historical models for regulating newly emerging technologies 
discussed by the PCSBI was the “Asilomar” conference, called by 
scientists in 1975 to discuss the implications of recently discovered 
techniques for recombinant DNA research.57  The conference was called 
in the context of a voluntary moratorium on recombinant DNA research 
that the scientific community imposed upon itself in light of concerns 
about the safety of the new technology.  The meetings at Asilomar led to 
the formation of guidelines to ensure safety and a scientific peer review 
group, today known as the Recombinant DNA Advisory Committee of 
the NIH.58  The Asilomar model, however, was most noted by the PCSBI 
as an example of self-regulation within the scientific community.59  
Analogizing synthetic biology to the state of recombinant DNA 
technology at the time of the 1975 Asilomar conference, the PCSBI 
argued that “the scientific community—in academia, government and 
the private sector—should continue to work together to evaluate and 
respond to known and potential risks of synthetic biology as this science 
evolves.”60  It went on to recommend that “[t]he government should 
support a continued culture of individual and corporate responsibility 
and self-regulation by the research community.”61  
Self regulation worked reasonably, even remarkably, well in the 
mid-1970’s, but there are several significant flaws with the PCSBI’s 
analogy to that era—not necessarily in terms of the character of the 
scientific breakthrough, but rather in terms of the context within which 
the breakthroughs occurred.  In the early 1970’s, genetic research was 
largely conducted in the confines of universities, and there was no 
biotechnology industry of which to speak.  Professors of molecular 
                                                 
57 Presidential Comm’n for the Study of Bioethical Issues, New Directions:  The Ethics of 
Synthetic Biology and Emerging Technologies, 38 (2010) [hereinafter New Directions]. 
58 Id.; see also SHELDON KRIMSKY, GENETIC ALCHEMY:  THE SOCIAL HISTORY OF THE 
RECOMBINANT DNA CONTROVERSY, 58–96, 126–64 (1982); Charles Weiner, Drawing the Line 
in Genetic Engineering:  Self-regulation and Public Participation, 44 PERSP. BIOLOGY & MED. 208 
(2001). 
59 New Directions, supra note 57, at 143. 
60 Id. at 145. 
61 Id. 
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biology were primarily researchers, not patent holders or CEOs.  
Historian Sheldon Krimsky notes that at the 1973 Gordon Conference, 
which paved the way to Asilomar, only eight of the one hundred and 
thirty scientists in attendance were from private industry.62  In this 
context, the practice of self-regulation involved calling on like-minded 
and similarly situated academic scientists to bear the major responsibility 
for  safe and intelligent development.  Krimsky notes that Asilomar thus 
represented “an important shift from individual to collective 
responsibility in this area of biological research.”63 
Yet even at Asilomar, we find the attraction of focusing on neat 
technological fixes for complex problems that implicate both scientific 
and social issues.  As Sheila Jasanoff noted, the scientists at Asilomar 
recognized that the new projects of emerging biotechnology were not 
to be lightly undertaken, but they also presumed that the 
route to greater understanding lay at the [molecular] 
level at which they were conducting their ingenious 
experiments, that is, at the level of molecular 
manipulation and control.  Molecules were small and 
relatively easy to understand, as well as inanimate, and 
thus safely removed from questions of politics or values.  
That biotechnology might one day destabilize basic 
elements of social order—kinship, for example, or 
farmers’ rights to own and sow seeds—was very far 
from the thoughts of the field’s founding fathers.64 
Soon after Asilomar, the relationship between academic research and 
industrial development of biotechnology began to transform rapidly.  
The year before the 1975 conference, Stanley Cohen, then an associate 
professor of medicine at Stanford University, and Herbert Boyer, a 
biochemist and genetic engineer at the University of California at San 
Francisco, filed a patent application for a “[p]rocess for [p]roducing 
[b]iologically [f]unctional [m]olecular [c]himeras.”  The patent, 
ultimately issued in 1980, together with two related patents formed the 
basis for modern gene-splicing recombinant DNA technology by using 
plasmids to transport foreign genes into bacteria.65  The patent provided 
the foundation for the first great biotechnology company, Genentech, 
                                                 
62 KRIMSKY, supra note 58, at 71, 72. 
63 Id. at 152–53. 
64 SHEILA JASANOFF, DESIGNS ON NATURE:  SCIENCE AND DEMOCRACY IN EUROPE AND THE 
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65 KRIMSKY, supra note 58, at 339; Rajendra K. Bera, The Story of the Cohen-Boyer Patents, 96 
CURRENT SCI. 760, 760–61 (2009). 
Valparaiso University Law Review, Vol. 45, No. 4 [2011], Art. 2
https://scholar.valpo.edu/vulr/vol45/iss4/2
2011] Synthetic Hype 1357 
which Boyer co-founded in 1976 with venture capitalist Robert A. 
Swanson.  The patent not only helped launch the modern biotechnology 
industry, but also “heralded a new era of university-industry 
relationships and set a standard for subsequent efforts to commercialize 
academic discoveries.”66  Stanford University (a co-holder to the patent 
rights) would go on to reap hundreds of millions of dollars from 
licensing the technology over the course of the patent’s life.67  Cohen and 
Boyer also came to symbolize a new model of academic-entrepreneur 
who could become a millionaire through commercializing (usually via 
the U.S. Patent and Trademark Office) his or her intellectual expertise. 
The same year Cohen and Boyer received their first patent, President 
Jimmy Carter signed into law two pieces of legislation that would come 
to transform relations between industry and academic researchers.  The 
first, the Stevenson-Wydler Technology Innovation Act of 1980,68 
encouraged interaction and cooperation among government laboratories, 
universities, big industries, and small businesses.69  The second, the 
Patent and Trademark Laws Amendment Act of 1980,70 commonly 
known as the Bayh-Dole Act, allowed institutions conducting research 
with federal funds, such as universities, to retain the intellectual 
property rights to their discoveries.71 
These developments transformed life science-related departments at 
major academic research institutions into profit centers that have come to 
drive university initiatives and priorities.  A significant shift in the focus 
and size of federal funding for research further spurred this 
transformation because massive amounts of money were poured into the 
life sciences and basic research funding for NIH far exceeded that offered 
to any other federal agency.  These agencies not only conduct research in 
their own right, but also are major sources of grants for academia.72 
                                                 
66 Maryann Feldman, Alessandra Colaianni & Kang Liu, Commercializing Cohen-Boyer 
1980–1997, DRUID Working Paper No. 05-21, 1 (2005),  available at http://www.druid.dk/ 
wp/pdf_files/Feldman_Colaianni_Liu.pdf. 
67 See id. 
68 15 U.S.C. §§ 3701–22 (2006). 
69 See 15 U.S.C. § 3701(3) (2006) (“Cooperation among academia, Federal laboratories, 
labor, and industry, in such forms as technology transfer, personnel exchange, joint 
research projects, and others, should be renewed, expanded, and strengthened.”). 
70 35 U.S.C. §§ 200–12 (2006). 
71 See id. § 200 (“It is the policy and objective of the Congress to use the patent system to 
promote the utilization of inventions arising from federally supported research or 
development”). 
72 2009 Budget Proposes Physical Sciences and Development Increases, Flat Funding for 
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Combined with changes to intellectual property law such as the 
Bayh-Dole Act, this massive infusion of funds into the life sciences has 
led to a concomitant proliferation in biotechnology patents.  The rise in 
such patents maps rather closely to the rise in federal funding for the 
NIH, which in turn is closely related to the massive federal investment in 
the HGP beginning in the early 1990s.73  Federal policy, exemplified by 
the HGP and combined with changes in intellectual property law, had a 
profound effect upon the structure and conceptualization of academia, 
transforming it into a major source of commercial activity.  No longer 
simply the sites of education and basic research, universities rapidly 
became major engines of capital enterprise, product development, and 
marketing.74 
Major research universities now seem to be engaged in a never 
ending hunt for the next biotechnological cash cow (or golden goose, for 
those who prefer fowl).  The promises of biotechnology have 
transformed universities into corporate partners, engaging in a myriad of 
commercial ventures and plowing millions of dollars into research aimed 
at providing return on investment, rather than the pursuit of core 
academic missions of teaching and broadly furthering basic knowledge. 
In 2007, the J. Craig Venter Institute together with the Center for 
Strategic & International Studies (“CSIS”), and the Massachusetts 
Institute of Technology published a report titled, “Synthetic Genomics:  
Options for Governance.”75  An example of industry-academia 
collaboration, the report referenced Asilomar in its introduction and 
referenced it throughout the report. 76  The report focused on the 
following areas: 
• Enhancing biosecurity, either by preventing incidents of 
bioterrorism or by helping law enforcement identify those 
responsible if incidents should occur. 
• Fostering laboratory safety, either by preventing accidents or by 
helping to respond in the event an accident does occur. 
• Protecting the environment, the people and natural ecosystems 
outside the laboratory.77 
                                                 
73 Nat’l Sci. Found., Table 5-28 Academic Patenting and Licensing Activities:  Selected years, 
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75 Michele S. Garfinkel et al., Synthetic Genomics:  Options for Governance (2007), available 
at http://www.jcvi.org/cms/fileadmin/site/research/projects/synthetic-genomics-report 
/synthetic-genomics-report.pdf. 
76 Id. at 7, 17, 39–40. 
77 Id. at 18. 
Valparaiso University Law Review, Vol. 45, No. 4 [2011], Art. 2
https://scholar.valpo.edu/vulr/vol45/iss4/2
2011] Synthetic Hype 1359 
These are important areas to address and relatively typical of how 
the risks of synthetic biology are frequently conceptualized.  However, 
they overlook such broad social and economic issues as the competition 
for the allocation of scarce resources and the diversion of intellectual 
capital from other avenues that seek to address the problems it aims to 
solve. 
In making its policy recommendations, the report purports a 
measure of agnosticism with respect to regulation, stating, “[w]e made 
no assumptions as to whether the options should be voluntary or legally 
binding (regulatory) in nature and if so, who the regulators should be.  
By the same token, we do not presuppose that the scientific community 
will automatically address these issues on its own.”78  While the report 
does discuss the place of government regulation, it tends to confine such 
oversight to the limited arena of licensing and record-keeping.  The 
report frequently consigns aspects of oversight to Institutional Biosafety 
Committees (“IBCs”), which were established under the NIH Guidelines 
for Recombinant DNA Research “to assess the biosafety and 
environmental risks of proposed recombinant DNA experiments 
conducted in academic and commercial settings, and to decide on the 
appropriate level of biocontainment.”79  While established under federal 
guidelines, such bodies are fundamentally private in nature and 
ultimately a form of self-regulation by the institutions that maintain 
them. 
In 2010, when biotechnology is a major component of our economy 
and professors in related fields are becoming millionaires and CEO’s off 
the fruits of their discoveries, the concept of self-regulation in 
biotechnology must take on very different connotations than it had in 
1975.  When scientists asked for caution and self-restraint in 1975, they 
were speaking largely to academic peers.  Today the audience of 
scientists being addressed are also entrepreneurs, many of whom are 
directly enmeshed in complex economic enterprises or working for 
academic institutions that have developed elaborate commercial 
relationships with private industry.  In this context, scientists cannot 
simply choose to self-regulate according to their best individual scientific 
judgment—they are also beholden to investors and corporate managers.  
Commercial imperatives must necessarily intrude upon scientific 
judgment in a manner inconceivable to the Asilomar scientists of 1975, 
hence the need to pay closer attention to the calls for an approach more 
fully informed by the precautionary principle. 
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Proceed with new technologies, by all means.  But proceed with 
caution.  The President’s Commission suggested we approach synthetic 
biology with “prudent vigilance.”  Perhaps, but I would suggest 
“skeptical vigilance” would be more in order. 
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